Cargando…

An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits variable immunity responses among hosts based on symptom severity. Whether immunity in recovered individuals is effective for avoiding reinfection is poorly understood. Determination of immune memory status against SARS-CoV-2 help...

Descripción completa

Detalles Bibliográficos
Autores principales: Soleimanian, Saeede, Alyasin, Soheila, Sepahi, Najmeh, Ghahramani, Zahra, Kanannejad, Zahra, Yaghobi, Ramin, Karimi, Mohammad Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163347/
https://www.ncbi.nlm.nih.gov/pubmed/35669767
http://dx.doi.org/10.3389/fimmu.2022.884879
_version_ 1784719898693337088
author Soleimanian, Saeede
Alyasin, Soheila
Sepahi, Najmeh
Ghahramani, Zahra
Kanannejad, Zahra
Yaghobi, Ramin
Karimi, Mohammad Hossein
author_facet Soleimanian, Saeede
Alyasin, Soheila
Sepahi, Najmeh
Ghahramani, Zahra
Kanannejad, Zahra
Yaghobi, Ramin
Karimi, Mohammad Hossein
author_sort Soleimanian, Saeede
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits variable immunity responses among hosts based on symptom severity. Whether immunity in recovered individuals is effective for avoiding reinfection is poorly understood. Determination of immune memory status against SARS-CoV-2 helps identify reinfection risk and vaccine efficacy. Hence, after recovery from COVID-19, evaluation of protective effectiveness and durable immunity of prior disease could be significant. Recent reports described the dynamics of SARS-CoV-2 -specific humoral and cellular responses for more than six months in convalescent SARS-CoV-2 individuals. Given the current evidence, NK cell subpopulations, especially the memory-like NK cell subset, indicate a significant role in determining COVID-19 severity. Still, the information on the long-term NK cell immunity conferred by SARS-CoV-2 infection is scant. The evidence from vaccine clinical trials and observational studies indicates that hybrid natural/vaccine immunity to SARS-CoV-2 seems to be notably potent protection. We suggested the combination of plasma therapy from recovered donors and vaccination could be effective. This focused review aims to update the current information regarding immune correlates of COVID-19 recovery to understand better the probability of reinfection in COVID-19 infected cases that may serve as guides for ongoing vaccine strategy improvement.
format Online
Article
Text
id pubmed-9163347
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91633472022-06-05 An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19 Soleimanian, Saeede Alyasin, Soheila Sepahi, Najmeh Ghahramani, Zahra Kanannejad, Zahra Yaghobi, Ramin Karimi, Mohammad Hossein Front Immunol Immunology Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits variable immunity responses among hosts based on symptom severity. Whether immunity in recovered individuals is effective for avoiding reinfection is poorly understood. Determination of immune memory status against SARS-CoV-2 helps identify reinfection risk and vaccine efficacy. Hence, after recovery from COVID-19, evaluation of protective effectiveness and durable immunity of prior disease could be significant. Recent reports described the dynamics of SARS-CoV-2 -specific humoral and cellular responses for more than six months in convalescent SARS-CoV-2 individuals. Given the current evidence, NK cell subpopulations, especially the memory-like NK cell subset, indicate a significant role in determining COVID-19 severity. Still, the information on the long-term NK cell immunity conferred by SARS-CoV-2 infection is scant. The evidence from vaccine clinical trials and observational studies indicates that hybrid natural/vaccine immunity to SARS-CoV-2 seems to be notably potent protection. We suggested the combination of plasma therapy from recovered donors and vaccination could be effective. This focused review aims to update the current information regarding immune correlates of COVID-19 recovery to understand better the probability of reinfection in COVID-19 infected cases that may serve as guides for ongoing vaccine strategy improvement. Frontiers Media S.A. 2022-05-20 /pmc/articles/PMC9163347/ /pubmed/35669767 http://dx.doi.org/10.3389/fimmu.2022.884879 Text en Copyright © 2022 Soleimanian, Alyasin, Sepahi, Ghahramani, Kanannejad, Yaghobi and Karimi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Soleimanian, Saeede
Alyasin, Soheila
Sepahi, Najmeh
Ghahramani, Zahra
Kanannejad, Zahra
Yaghobi, Ramin
Karimi, Mohammad Hossein
An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
title An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
title_full An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
title_fullStr An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
title_full_unstemmed An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
title_short An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
title_sort update on protective effectiveness of immune responses after recovery from covid-19
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163347/
https://www.ncbi.nlm.nih.gov/pubmed/35669767
http://dx.doi.org/10.3389/fimmu.2022.884879
work_keys_str_mv AT soleimaniansaeede anupdateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT alyasinsoheila anupdateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT sepahinajmeh anupdateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT ghahramanizahra anupdateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT kanannejadzahra anupdateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT yaghobiramin anupdateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT karimimohammadhossein anupdateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT soleimaniansaeede updateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT alyasinsoheila updateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT sepahinajmeh updateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT ghahramanizahra updateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT kanannejadzahra updateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT yaghobiramin updateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19
AT karimimohammadhossein updateonprotectiveeffectivenessofimmuneresponsesafterrecoveryfromcovid19